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CASE 2
A 66-year-old right-hand-dominant African American woman presented to the clinic with masses of the right index and left middle fingers. Her medical history consisted of RCC without signs of systemic disease, treated with robotic nephrectomy and chemotherapy. Physical examination revealed swelling of the right index and left middle fingers (Fig. 3) .
She had full range of motion but tenderness to palpation at the tumor sites. Radiographs reveal an extensive osteolytic lesion in the distal phalanx of the left middle finger (Fig. 4) . Surgical treatment consisted of palliative amputation to the distal phalanx of the right index finger and middle phalanx of the left middle finger (Fig. 3) . Without complications from this procedure, the patient's disease progressed resulting in death 4 months later.
DISCUSSION AND REVIEW OF LITERATURE
British surgeon Handley 4 first described the rare phenomenon of acrometastasis to the hand in 1906 when reporting a case of a woman with breast carcinoma later developing multiple metacarpal metastases. In 2008, Flynn et al 3 reviewed 257 cases demonstrating the distal phalanx as the most common site of metastasis, followed by the metacarpal, proximal phalanx, middle phalanx, and the carpals. Almost half of these cases stemmed from primary lung (44%), kidney (12%), breast (10%), and colon cancers (6%). 3 Since then, 29 more cases have been reported including primary pulmonary, renal, and vaginal carcinomas 5 and follicular carcinoma of the thyroid. 6 Clinical presentation is a painful, warm, swollen, and/or erythematous lesion usually resulting in functional impairment. Advanced tumors can appear ulcerated and cause severe irritation. Radiologic appearance demonstrated by irregular osteolytic lesions lacking a periosteal reaction 7 coupled with the presence of a history of malignancy should raise suspicion for acrometastasis, although the differential diagnosis includes gout, rheumatoid arthritis, whitlow, osteomyelitis, fistula, and osteoarthropathy.
Estimated that 10% of acrometastasis become symptomatic before a primary tumor is discovered, 8 it was the initial presentation of occult tumors in 10 of the 29 (34%) reported cases since 2008. Patients were misdiagnosed with osteoarthritis or infection based on presentation. 9, 10 Radiographic osteolytic changes prompted a malignancy work-up after histo- reported one case of persistent pain 3 months before radiographic changes increasing the need for high suspicion of acrometastasis in persistent pain refractory to nonsteroidal anti-inflammatory drugs or antibiotics.
Not limited to bone, acrometastasis to the skin and soft tissues without skeletal involvement can also occur. Aydin et al 12 reported a laryngeal carcinoma metastasizing to skin overlying the palmar surface of the left fifth metacarpal joint, and Afshar et al 13 reported a gestational choriocarcinoma metastasizing to the junction of the hyponychium and nail bed of the small finger of the dominant hand.
The mechanism of acrometastasis remains poorly understood. The phalangeal absence of bone marrow has led to alternative theories for hematologic spread 14 including increased blood flow and trauma. The release of prostaglandins and local chemotactic factors can promote cell migration and adherence to bone. 8 Observation that dominant hand metastasis occurs more commonly supports this theory as that hand receives more blood flow and is more prone to trauma than the nondominant hand. 15 Given the advanced stage of disease upon presentation with a mean survival of 6 months, the goal of treatment is palliation. 3 Although zoledronic acid and denosumab are often indicated to treat bone metastasis of primary solid tumors, their primary mechanism of action is the inhibition of osteoclasts from resorbing bone, limiting their use in acrometastasis where osteolysis has already occurred. 16 Early detection, as in the case of Bhandari and Brown, 11 may benefit from these medications to prevent progression.
Unfortunately, acrometastasis is usually detected late, making aggressive modalities such as curettage, wide excision, chemotherapy, radiation, and amputation necessary to achieve palliation. 6 The lesion site also contributes to the treatment approach. Proximal and thumb lesions are best managed conservatively with radiation providing immediate pain relief while maintaining normal function. 17, 18 Distal lesions or lesions unresponsive to radiation require palliative amputation to provide comfort in the patient's end of life.
3 Acrometastasis represents a poor prognosis with a survival rate of approximately 1 year with therapy 19 ; therefore, reconstruction is not typically considered unless the patient remains tumor free for 2 to 3 years.
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CONCLUSION
Acrometastasis from a primary RCC or HCC is a rare condition carrying grave prognostic indicators. It is important for plastic hand surgeons treating patients to understand implications of discovering such a lesion; although curative resection is unlikely, palliative resection should be considered. 
